Source:http://linkedlifedata.com/resource/pubmed/id/16567054
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-5-22
|
pubmed:abstractText |
We examined the role of cyclooxygenase-2 in the development of ischemic tolerance induced by cortical spreading depression against transient, focal brain ischemia. Cortical spreading depression was continuously induced for 2 h with topical KCl (13+/-1 depolarizations/2 h) in male Wistar rats. At 1, 2, 3, 4, and 5 days following recovery, the middle cerebral artery was transiently occluded for 120 min. Four days later, the animals were killed and infarct volume was determined. Additionally, cyclooxygenase-2 levels in the cerebral cortex and 15 deoxy-Delta(12, 14) PGJ2 levels in cerebrospinal fluid were determined at these times with Western blotting and immunoassay, respectively. Infarct volume was reduced compared with non-cortical spreading depression control animals (274.3+/-15.3 mm3) when cortical spreading depression was performed 3 and 4 days before middle cerebral artery occlusion (163.9+/-14.2 mm3, 154.9+/-14.2 mm3) but not at 1, 2 and 5 days (280.4+/-17.3 mm3, 276.3+/-16.9 mm3 and 268.5+/-17.3 mm3). Cyclooxygenase-2 levels increased most dramatically starting at 2 days, peaked at 3 days, and started to return toward baseline at 4 days after cortical spreading depression. 15 Deoxy-Delta(12, 14) PGJ2 levels increased from 134.7+/-83 pg/ml at baseline to 718+/-98 pg/ml at 3 days. Administration of N-[2-cyclohexyloxy-4-nitrophenyl] methanesulphonamide (10 mg/kg, i.v.), a selective cyclooxygenase-2 inhibitor, at 1 h prior to middle cerebral artery occlusion in cortical spreading depression preconditioned animals did not affect infarct volume (162.6+/-62.1 mm3). However, administration of N-[2-cyclohexyloxy-4-nitrophenyl] methanesulphonamide given three times prior to middle cerebral artery occlusion prevented the reduced infarct volume induced by cortical spreading depression preconditioning (272.9+/-63.2 mm3). Administration of L-nitro-arginine methyl ester (4 mg/kg, i.v.) prior to cortical spreading depression blocked increases in cyclooxygenase-2 normally seen at 3 and 4 days. We conclude that NO-mediated cyclooxygenase-2 upregulation by cortical spreading depression protects the brain against ischemic damage.
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/DK62372,
http://linkedlifedata.com/resource/pubmed/grant/HL30260,
http://linkedlifedata.com/resource/pubmed/grant/HL46558,
http://linkedlifedata.com/resource/pubmed/grant/HL50587,
http://linkedlifedata.com/resource/pubmed/grant/HL66074,
http://linkedlifedata.com/resource/pubmed/grant/HL77731
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/9-deoxy-delta-9-prostaglandin D2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/NG-Nitroarginine Methyl Ester,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/Potassium Chloride,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin D2
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0306-4522
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
30
|
pubmed:volume |
140
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
723-30
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:16567054-Animals,
pubmed-meshheading:16567054-Cerebral Cortex,
pubmed-meshheading:16567054-Cerebral Infarction,
pubmed-meshheading:16567054-Cortical Spreading Depression,
pubmed-meshheading:16567054-Cyclooxygenase 2,
pubmed-meshheading:16567054-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:16567054-Cytoprotection,
pubmed-meshheading:16567054-Disease Models, Animal,
pubmed-meshheading:16567054-Infarction, Middle Cerebral Artery,
pubmed-meshheading:16567054-Ischemic Attack, Transient,
pubmed-meshheading:16567054-Ischemic Preconditioning,
pubmed-meshheading:16567054-Male,
pubmed-meshheading:16567054-NG-Nitroarginine Methyl Ester,
pubmed-meshheading:16567054-Nitric Oxide,
pubmed-meshheading:16567054-Nitric Oxide Synthase,
pubmed-meshheading:16567054-Potassium Chloride,
pubmed-meshheading:16567054-Prostaglandin D2,
pubmed-meshheading:16567054-Rats,
pubmed-meshheading:16567054-Rats, Wistar,
pubmed-meshheading:16567054-Up-Regulation
|
pubmed:year |
2006
|
pubmed:articleTitle |
Cyclooxygenase-2 mediates the development of cortical spreading depression-induced tolerance to transient focal cerebral ischemia in rats.
|
pubmed:affiliation |
Department of Physiology and Pharmacology, Wake Forest University Health Sciences, USA, and Department of Neurosurgery, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka Meguro-ku, Tokyo, Japan. takaholy@aol.com
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|